SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

MB-07811

Item No. 30670

CAS Registry No.:	852948-13-1
Formal Name:	4-[[4-[[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]methoxy]-2,6-dimethylphenyl]methyl]-2-(1-methylethyl)-phenol
Synonym:	VK-2809
MF:	$C_{28}H_{32}ClO_5P$
FW:	515.0
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

MB-07811 is supplied as a solid. A stock solution may be made by dissolving the MB-07811 in the solvent of choice, which should be purged with an inert gas. MB-07811 is soluble in organic solvents such as acetonitrile and DMSO.

Description

MB-07811 is a liver-targeted prodrug form of the thyroid hormone receptor β (TRβ) agonist MB-07344.[1] It is stable in extrahepatic tissues and converted to MB-07344 in the liver. MB-07811 binds to TRα1 and TRβ1 with K_i values of 12.5 and 14.6 µM, respectively. Oral administration of MB-07811 reduces plasma cholesterol levels (ED_{50} = 0.48 mg/kg) in a cholesterol-fed rat (CFR) model. It also reduces hepatic steatosis, as well as plasma levels of cholesterol, in Zucker diabetic fatty rats in a model of non-alcoholic fatty liver disease (NAFLD) when administered at a dose of 5 mg/kg per day.[2] MB-07811 (10 mg/kg) reverses hepatic steatosis, reducing total hepatic lipids without decreasing body weight, in a mouse model of diet-induced obesity.

References

1. Boyer, S.H., Jiang, H., Jacintho, J.D., *et al.* Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs. *J. Med. Chem.* **51(22)**, 7075-7093 (2008).
2. Cable, E.E., Finn, P.D., Stebbins, J.W., *et al.* Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. *Hepatology* **49(2)**, 407-417 (2009).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM